Literature DB >> 27821317

Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

Joerg Heil1, Benedikt Schaefgen2, Peter Sinn3, Hannah Richter2, Aba Harcos2, Christina Gomez2, Anne Stieber2, André Hennigs2, Geraldine Rauch4, Florian Schuetz2, Christof Sohn2, Andreas Schneeweiss5, Michael Golatta2.   

Abstract

BACKGROUND: This study aimed to explore the ability of a minimal invasive biopsy to diagnose a pathological complete response (pCR = ypT0) in the breast.
METHODS: Ultrasound-guided, vacuum-assisted, minimal invasive biopsy (VAB) was performed in 50 patients after neoadjuvant chemotherapy and before breast surgery. Negative predictive values (NPV) and false negative rates (FNR) to predict a pCR in surgical specimen were the main outcome measures. To assess the possible sampling error, the representativeness of the sample was evaluated by the biopsy performing physician (subjectively based on the visibility in ultrasound), by radiography of the biopsy specimen, and by the pathologist (based on histopathology).
RESULTS: The cohort (n = 50) consisted of 15 (30%) triple negative breast cancers, 13 (26%) human epidermal growth factor receptor 2 (HER2) positive and 22 (44%) hormone receptor positive/HER2 negative cancers. ypT0 was diagnosed in 23 (46%) cases. In the overall cohort (n = 50), VAB yielded an NPV of 76.7% and an FNR of 25.9%. Given a representative VAB sample, according to the histopathological evaluation (n = 38), the NPV was 94.4% (95% CI 87.1-100.0) and the FNR 4.8% (95% CI 0.0-11.6). Non-representative VABs were mainly due to bad visibility of the target lesion in ultrasound.
CONCLUSION: A VAB can accurately diagnose a pCR, given a histopathologically representative sample. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Invasive breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Vacuum-assisted biopsy

Mesh:

Substances:

Year:  2016        PMID: 27821317     DOI: 10.1016/j.ejca.2016.09.034

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer.

Authors:  R F D van la Parra; A B Tadros; C M Checka; G M Rauch; A Lucci; B D Smith; S Krishnamurthy; V Valero; W T Yang; H M Kuerer
Journal:  Br J Surg       Date:  2018-02-21       Impact factor: 6.939

2.  MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer.

Authors:  Stephen F Sener; Rachel E Sargent; Connie Lee; Tejas Manchandia; Vivian Le-Tran; Yuliya Olimpiadi; Nicole Zaremba; Andrew Alabd; Maria Nelson; Julie E Lang
Journal:  J Surg Oncol       Date:  2019-08-09       Impact factor: 3.454

3.  Optimal Selection of Breast Cancer Patients for Elimination of Surgery Following Neoadjuvant Systemic Therapy.

Authors:  Henry M Kuerer; Savitri Krishnamurthy; Gaiane M Rauch; Wei T Yang; Benjamin D Smith; Vicente Valero
Journal:  Ann Surg       Date:  2018-12       Impact factor: 12.969

Review 4.  Innovative Standards in Surgery of the Breast after Neoadjuvant Systemic Therapy.

Authors:  Tal Hadar; Michael Koretz; Mahmood Nawass; Tanir M Allweis
Journal:  Breast Care (Basel)       Date:  2021-11-02       Impact factor: 2.860

Review 5.  A review of studies on omitting surgery after neoadjuvant chemotherapy in breast cancer.

Authors:  Kexin Feng; Ziqi Jia; Gang Liu; Zeyu Xing; Jiayi Li; Jiaxin Li; Fei Ren; Jiang Wu; Wenyan Wang; Jie Wang; Jiaqi Liu; Xiang Wang
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

6.  Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting.

Authors:  Frederik Knude Palshof; Charlotte Lanng; Niels Kroman; Cemil Benian; Ilse Vejborg; Anne Bak; Maj-Lis Talman; Eva Balslev; Tove Filtenborg Tvedskov
Journal:  Ann Surg Oncol       Date:  2021-05-27       Impact factor: 5.344

7.  Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour.

Authors:  Soo-Yeon Kim; Nariya Cho; Sung Ui Shin; Han-Byoel Lee; Wonshik Han; In Ae Park; Bo Ra Kwon; Soo Yeon Kim; Su Hyun Lee; Jung Min Chang; Woo Kyung Moon
Journal:  Eur Radiol       Date:  2018-01-29       Impact factor: 5.315

Review 8.  The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.

Authors:  Roberto A Leon-Ferre; Tina J Hieken; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2021-01-23       Impact factor: 5.344

9.  Minimally Invasive Complete Response Assessment of the Breast After Neoadjuvant Systemic Therapy for Early Breast Cancer (MICRA trial): Interim Analysis of a Multicenter Observational Cohort Study.

Authors:  Ariane A van Loevezijn; Marieke E M van der Noordaa; Erik D van Werkhoven; Claudette E Loo; Gonneke A O Winter-Warnars; Terry Wiersma; Koen K van de Vijver; Emilie J Groen; Charlotte F J M Blanken-Peeters; Bas J G L Zonneveld; Gabe S Sonke; Frederieke H van Duijnhoven; Marie-Jeanne T F D Vrancken Peeters
Journal:  Ann Surg Oncol       Date:  2020-12-02       Impact factor: 5.344

10.  Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer.

Authors:  Jiujun Zhu; Dechuang Jiao; Min Yan; Xiuchun Chen; Chengzheng Wang; Zhenduo Lu; Lianfang Li; Xianfu Sun; Li Qin; Xuhui Guo; Chongjian Zhang; Jianghua Qiao; Jianbin Li; Zhimin Fan; Haibo Wang; Jianguo Zhang; Yongmei Yin; Peifen Fu; Cuizhi Geng; Feng Jin; Zefei Jiang; Shude Cui; Zhenzhen Liu
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.